Jump to content

Zactima (TM) Shows Promise Against NSCLC


Recommended Posts

http://professional.cancerconsultants.c ... x?id=43641


. . . . . . . . .


Zactima™ Shows Promise Against Non–Small Cell Lung Cancer

Researchers affiliated with the ZODIAC international Phase III clinical trial have reported that the addition of Zactima™ (vandetanib) to Taxotere® (docetaxel) delayed time to progression among patients with previously treated, advanced non–small cell lung cancer (NSCLC). The details of this study were presented on May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.

Zactima is a once-daily oral agent targeted against vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), as well as rearranged during transfection (RET) tyrosine kinases. The activity against these three targets makes Zactima a promising new agent.

Researchers involved in an international randomized Phase II clinical trial have shown that Zactima™ may be more effective than Iressa® (gefitinib) for second-line therapy of patients with locally advanced or metastatic NSCLC. The details of this study appeared in the May 20, 2009 issue of the Journal of Clinical Oncology.

In this study 1,391 patients with advanced NSCLC who had been previously treated with chemotherapy were randomly allocated to receive Taxotere with or without Zactima. Patients have now been followed for roughly one year.

The addition of Zactima prolonged time to disease progression from 14 weeks in patients receiving Taxotere to 17.3 weeks. Overall survival did not differ significantly between the two study groups.

Patients treated with Zactima experienced an improvement in cancer symptoms.

Side effects that were more common among patients treated with Zactima included diarrhea, rash, and low white blood cell counts.

Comments: These results suggest that the addition of Zactima to second-line chemotherapy for NSCLC may delay cancer progression and reduce cancer symptoms

. . . . . . . . .

(CancerConsultants.com, Oncology Resource Center, Information presented May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.)


The information contained in these articles may or may not be in agreement with my own opinions. They are not being posted with the intention of being medical advice of any kind.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.